Final Program N
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Trauma Treating Traumatic Facial Nerve Paralysis
LETTERS TO EDITOR 205 206 LETTERS TO EDITOR In conclusion, the most frequent type of HBV R. Hepatitis B virus genotype A is more often hearing loss, and an impedance audiogram Strands of facial nerve interconnect with genotype in our study was D type, which associated with severe liver disease in northern showed absent stapedial reflex. CT scan cranial nerves V, VIII, IX, X, XI, and XII and usually causes a mild liver disease. Hence India than is genotype D. Indian J Gastroenterol showed no fracture of the temporal bone and with the cervical cutaneous nerves. This free proper vaccination, e ducational programs, 2005;24:19-22. intact ossicles. The patient was prescribed intermingling of Þ bers of the facial nerve with and treatment with lamivudine are efficient 6. Thakur V, Sarin SK, Rehman S, Guptan RC, high-dose steroids, along with vigorous facial Þ bers of other neural structures (particularly Kazim SN, Kumar S. Role of HBV genotype strategies in controlling HBV infection in our nerve stimulation and massages. the cranial nerve V) has been proposed as in predicting response to lamivudine therapy area. the mechanism of spontaneous return of facial in patients with chronic hepatitis B. Indian J After 3 weeks of treatment, the facial nerve nerve function after peripheral injury to the Gastroenterol 2005;24:12-5. stimulation tests were repeated and the ABDOLVAHAB MORADI, nerve.[4] VAHIDEH KAZEMINEJHAD1, readings were compared to those taken prior to GHOLAMREZA ROSHANDEL, treatment. There was negligible improvement. KHODABERDI KALAVI, Early onset/complete palsy indicates disruption EZZAT-OLLAH GHAEMI2, SHAHRYAR SEMNANI The patient was offered an exploratory of continuity of the nerve. -
Middle Ear Disorders
3/2/2014 ENT CARRLENE DONALD, MMS PA-C ANTHONY MENDEZ, MMS PA-C MAYO CLINIC ARIZONA DEPARTMENT OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY No Disclosures OBJECTIVES • 1. Identify important anatomic structures of the ears, nose, and throat • 2. Assess and treat disorders of the external, middle and inner ear • 3. Assess and treat disorders of the nose and paranasal sinuses • 4. Assess and treat disorders of the oropharynx and larynx • 5. Educate patients on the risk factors for head and neck cancers 1 3/2/2014 Otology External Ear Disorders External Ear Anatomy 2 3/2/2014 Trauma • Variety of presentations. • Rule out temporal bone trauma (battle’s sign & hemotympanum). CT head w/out contrast. • Tx lacerations/avulsions with copious irrigation, closure with dissolvable sutures (monocryl), tetanus update, and antibiotic coverage (anti- Pseudomonal). May need to bolster if concerned for a hematoma . Auricular Hematoma • Due to blunt force trauma. • Drain/aspirate, cover with anti- biotics (anti- Pseudomonals), and apply bolster or passive drain if needed. • Infection and/or cauliflower ear may result if not treated. Chondritis • Inflammation and infection of the auricular cartilage. usually due to Pseudomonas aeruginosa. • Cultures • Treat with empiric antibiotics (anti-Pseudomonal) and I&D if needed. • Differentiate from relapsing polychondritis, which is an autoimmune disorder. 3 3/2/2014 External Auditory Canal Foreign Body • Children –Foreign bodies • Adults – Cerumen plugs • May present with hearing loss, ear pain and drainage • Exam under microscopic otoscopy. Check for otitis externa. • Remove under direct visualization. Can try to neutralize bugs with mineral oil. Do not attempt to irrigate organic material with water as this may cause an infection. -
List of Patented Medicines 2018
Patented Medicine Annual Report List 02 Apr 2019 Prices Review Board Protected A DIN Brand Chemical Name ATC Dosage Comments Status ABBVIE 02436027 HOLKIRA PAK 12.5/75/50/250 ombitasvir/paritaprevir/ritonavir/dasabuvir J05AX Oral Solid /Tablet Within Guidelines 02258595 HUMIRA - 40 MG/SYRINGE adalimumab L04AA Parenteral /Solution Within Guidelines 02312301 KALETRA 100/25 MG/TABLET lopinavir/ritonavir J05AE Oral Solid /Tablet Within Guidelines 02285533 KALETRA 200/50 MG/TABLET lopinavir/ritonavir J05AE Oral Solid /Tablet Within Guidelines 02243644 KALETRA 80/20 MG/MILLILITER lopinavir/ritonavir J05AE Oral Liquid /Solution Does Not Trigger 00884502 LUPRON DEPOT - 3.75 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 00836273 LUPRON DEPOT - 7.5 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02239834 LUPRON DEPOT - 11.25 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02230248 LUPRON DEPOT - 22.5 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02239833 LUPRON DEPOT - 30 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02467550 MAVIRET 100/40 MG/TABLET glecaprevir/pibrentasvir J05AP Oral Solid /Tablet Subj. Investigation 02229145 NORVIR - 80 MG/MILLILITER ritonavir J05AE Oral Liquid /Solution Within Guidelines 02357593 NORVIR - 100 MG/TABLET ritonavir J05AE Oral Solid /Tablet Within Guidelines 02481332 ORILISSA - 150 MG/TABLET elagolix -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
Human and Recombinat Coagulation Factor VIII
08 July 2016 EMA/PRAC/471535/2016 PRAC List of questions To be addressed by the marketing authorisation holder(s) for human and recombinant coagulation factor VIII containing medicinal products Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data Procedure number: EMEA/H/A-31/1448 Advate EMEA/H/C/0520/A31/0078 Elocta EMEA/H/C/3964/A31/0006 Helixate Nexgen EMEA/H/C/0276/A31/0178 Iblias EMEA/H/C/4147/A31/0002 Kogenate EMEA/H/C/0275/A31/0185 Kovaltry EMEA/H/C/3825/A31/0004 Novoeight EMEA/H/C/2719/A31/0014 Nuwiq EMEA/H/C/2813/A31/0015 Obizur EMEA/H/C/2792/A31/0003 Refacto AF EMEA/H/C/0232/A31/0134 Voncento EMEA/H/C/2493/A31/0022 Active substances: human coagulation factor VIII; efmoroctocog alfa; moroctocog alfa; octocog alfa; simoctocog alfa; susoctocog alfa; turoctocog alfa 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 1. Background Today’s standard treatment of congenital haemophilia (and acquired haemophilia A) is based on prophylactic or on-demand replacement therapy with coagulation factor VIII (FVIII), either with plasma derived or with recombinant FVIII products. Principally both substance classes may be used for prophylactic treatment as well as for therapeutic treatment in case of spontaneous bleedings. Inhibitor development in haemophilia A patients receiving FVIII products mostly occurs in previously untreated or minimally treated patients (PUPs), who are still within the first 50 days of exposure to the treatment. -
PASS) Information
Reference Number: RD-SOP-1214 Supplement Version: 14 Post Authorization Safety Study (PASS) Information HA-SAFE: Observational study evaluating long-term safety Acronym/Title of real-world treatment with damoctocog alfa pegol in previously treated patients with hemophilia A Protocol version and date v 1.0, 13 JAN 2020 IMPACT study number 20904 Study type / Study phase Observational, post-approval PASS Joint PASS: YES NO EU PAS register number Study not yet registered Active substance ATC code: B02BD02/Hematological/Damoctocog alfa pegol Medicinal product Jivi EU/1/18/1324/001 Jivi 250 IU; Product reference EU/1/18/1324/002 Jivi 500 IU; EU/1/18/1324/003 Jivi 1000 IU; EU/1/18/1324/004 Jivi 2000 IU; EU/1/18/1324/005 Jivi 3000 IU Procedure number EMEA/H/C/004054 Study Initiator and Funder Bayer Consumer Care AG, Basel, Switzerland Research question and objectives The aim of this study is to characterize in a real-world setting the long-term safety of damoctocog alfa pegol drug usage. The primary objective of this study is to assess the long- term safety of prophylaxis with damoctocog alfa pegol in patients with hemophilia A in the real-world setting through the collection and analysis of adverse events (AEs) of special interest including those potentially indicative of PEG accumulation (hypersensitivity reactions, loss of drug effect, renal impairment, neurocognitive disorders, and inhibitor development), AEs, serious adverse events (SAEs), and adverse reactions (ARs). The secondary objective is to monitor the clinical effects of long-term exposure of prophylaxis damoctocog alfa pegol in 20904; HA-SAFE; v 1.0, 13 JAN 2020 Page 1 of 48 Reference Number: RD-SOP-1214 Supplement Version: 14 patients with hemophilia A, including assessments of kidney and liver function parameters, neurological function and patients’ PEG plasma levels. -
CHMP/565731/2018 Rev.1 Inspections, Human Medicines Pharmacovigilance and Committees Division
21 August 2018 EMA/CHMP/565731/2018 Rev.1 Inspections, Human Medicines Pharmacovigilance and Committees Division Committee for medicinal products for human use (CHMP) Agenda of CHMP written procedure* 20-23 August 2018 Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann * Written Procedure - comments on the draft documents should be forwarded to the Product Manager (PM) as identified in the CHMP agenda. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. -
ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4
ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH 2012 11.6.2012 14:46 Page 1 Table of Contents 3 Welcome Message from the Meeting President 3 Welcome Message from ISTH Council Chairman 4 Welcome Message from SSC Chairman 5 Committees 7 ISTH Future Meetings Calendar 8 Meeting Sponsors 9 Awards and Grants 2012 12 General Information 20 Programme at a Glance 21 Day by Day Scientific Schedule & Programme 22 Detailed Programme Tuesday, 26 June 2012 25 Detailed Programme Wednesday, 27 June 2012 33 Detailed Programme Thursday, 28 June 2012 44 Detailed Programme Friday, 29 June 2012 56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles 110 Exhibition Floor Plan 111 Congress Centre Floor Plan www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3 WelcomeCommittees Messages Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council Messages Dear Colleagues and Friends, Dear Colleagues and Friends, We warmly welcome you to the elcome It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on Thrombosis and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants. -
PRAC Draft Agenda of Meeting 4 -7 March 2013
4 March 2013 EMA/PRAC/141813/2013 Pharmacovigilance Risk Assessment Committee (PRAC) Pharmacovigilance Risk Assessment Committee (PRAC) Agenda of the meeting on 4-7 March 2013 Explanatory notes The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda. EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures (Items 2 and 3 of the PRAC agenda) A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid =WC0b01ac05800240d0 Signals assessment and prioritisation (Item 4 of the PRAC agenda) A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks. The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. -
Åäãíàâëäàâ Êöéàéç 2017 Íóï 9
ISSN 2074-9848 e-ISSN 2310-0532 ÅÄãíàâëäàâ êÖÉàéç 2017 íÓÏ 9 № 2 ä‡ÎËÌËÌ„ð‡‰ àÁ‰‡ÚÂθÒÚ‚Ó Å‡ÎÚËÈÒÍÓ„Ó Ù‰Âð‡Î¸ÌÓ„Ó ÛÌË‚ÂðÒËÚÂÚ‡ ËÏÂÌË àÏχÌÛË· ä‡ÌÚ‡ 2017 1 БАЛТИЙСКИЙ Редакционная коллегия РЕГИОН А. П. Клемешев, д-р полит. наук, проф., ректор БФУ им. И. Кан- та — главный редактор (Россия); Г. М. Федоров, д-р геогр. 2017 наук, проф., директор Института природопользования, терри- ториального развития и градостроительства, БФУ им. И. Кан- Том 9 та — зам. главного редактора (Россия); Й. фон Браун, дирек- тор Центра изучения развития, проф., Боннский университет № 2 (Германия); И. М. Бусыгина, д-р полит. наук, проф. кафедры сравнительной политологии, МГИМО (У) МИД РФ (Россия); Калининград : В. В. Воронов, д-р социол. наук, ведущий исследователь Инсти- тута социальных исследований, Даугавпилсский универси- Изд-во БФУ тет (Латвия); А. Г. Дружинин, д-р геогр. наук, директор Севе- им. И. Канта, 2017. ро-Кавказского научно-исследовательского института экономи- 185 с. ческих и социальный проблем, ЮФУ (Россия); М. В. Ильин, д-р полит. наук, проф. кафедры сравнительной политологии, Журнал основан МГИМО (У) МИД РФ (Россия); П. Йонниеми, старший науч- в 2009 году ный сотрудник, Карельский институт, Университет Восточ- ной Финляндии (Финляндия); Н. В. Каледин, канд. геогр. наук, Периодичность: доц., зав. каф. региональной политики и политической гео- графии, СПбГУ (Россия); В. А. Колосов, д-р геогр. наук, проф., 4 номера в год зав. лабораторией геополитических исследований, Институт на русском географии РАН (Россия); Г. В. Кретинин, д-р ист. наук, проф., и английском языках Институт гуманитарных наук, БФУ им. И. Канта (Россия); К. Люхто, проф., директор Пан-Европейского института выс- Учредители: шей школы экономики, Университет г. -
Characterization of a Novel Metalloproteinase in Duvernoy's Gland of Rhabdophis Tigrinus Tigrinus
The Journal of Toxicological Sciences, 157 Vol.31, No.2, 157-168, 2006 CHARACTERIZATION OF A NOVEL METALLOPROTEINASE IN DUVERNOY’S GLAND OF RHABDOPHIS TIGRINUS TIGRINUS Koji KOMORI1, Motomi KONISHI1, Yuji MARUTA1, Michihisa TORIBA2, Atsushi SAKAI2, Akira MATSUDA3, Takamitsu HORI3, Mitsuko NAKATANI4, Naoto MINAMINO4 and Toshifumi AKIZAWA1 1Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotogecho, Hirakata, Osaka 573-0101, Japan 2The Japan Snake Institute, 3318 Yabuzuka Ota, Gunma 379-2301, Japan 3Department of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan 4Department of Pharmacology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan (Received January 31, 2006; Accepted February 20, 2006) ABSTRACT — During the characterization of hemorrhagic factor in venom of Rhabdophis tigrinus tigri- nus, so-called Yamakagashi in Japan, one of the Colubridae family, a novel metalloproteinase with molec- ular weight of 38 kDa in the Duvernoy’s gland of Yamakagashi was identified by gelatin zymography and by monitoring its proteolytic activity using a fluorescence peptide substrate, MOCAc-PLGLA2pr(Dnp)AR-NH2, which was developed for measuring the well-known matrix metalloproteinase (MMP) activity. After purification by gel filtration HPLC and/or column switch HPLC system consisting of an affin- ity column, which was immobilized with a synthetic BS-10 peptide (MQKPRCGVPD) originating from propeptide domain of MMP-7 and a reversed-phase column, the N-terminal amino acid sequence of the 38 kDa metalloproteinase was identified as FNTFPGDLK which shared a high homology to Xenopus MMP-9. The 38 kDa metalloproteinase required Zn2+ and Ca2+ ions for its proteolytic activity. -
Approach to the Trauma Patient Will Help Reduce Errors
The Approach To Trauma Author Credentials Written by: Nicholas E. Kman, MD, The Ohio State University Updated by: Creagh Boulger, MD, and Benjamin M. Ostro, MD, The Ohio State University Last Update: March 2019 Case Study “We have a motor vehicle accident 5 minutes out per EMS report.” 47-year-old male unrestrained driver ejected 15 feet from car arrives via EMS. Vital Signs: BP: 100/40, RR: 28, HR: 110. He was initially combative at the scene but now difficult to arouse. He does not open his eyes, withdrawals only to pain, and makes gurgling sounds. EMS placed a c-collar and backboard, but could not start an IV. What do you do? Objectives Upon completion of this self-study module, you should be able to: ● Describe a focused rapid assessment of the trauma patient using an organized primary and secondary survey. ● Discuss the components of the primary survey. ● Discuss possible pathology that can occur in each domain of the primary survey and recommend treatment/stabilization measures. ● Describe how to stabilize a trauma patient and prioritize resuscitative measures. ● Discuss the secondary survey with particular attention to head/central nervous system (CNS), cervical spine, chest, abdominal, and musculoskeletal trauma. ● Discuss appropriate labs and diagnostic testing in caring for a trauma patient. ● Describe appropriate disposition of a trauma patient. Introduction Nearly 10% of all deaths in the world are caused by injury. Trauma is the number one cause of death in persons 1-50 years of age and results in significant life years lost. According to the National Trauma Data Bank, falls were the leading cause of trauma followed by motor vehicle collisions (MVCs) and firearm related injuries with an overall mortality rate of 4.39% in 2016.